Cabel - If I heard the story correctly RVX/ZEL had between 30 and 40 meetings during the Bio Showcase conference. I don't know if any CDA's were signed but I think it's a pretty good bet that a number of BP's have been doing DD for quite some time now. This is nothing more than what you would expect for a small company at this point in a Phase III trial. If we succeed in reaching our primary end point this thing could explode. Between diabetic cardio, CKD and dementia the G8 market should eventually exceed 100 million potential patients. That's a really big potential market. If you were a BP that didn't want to get left behind would you wait until this first in class drug passed the trial before starting your DD?

All IMO, dyodd.

tada